drugset / Trial / NCT05591755

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

NCT05591755

Phase 3 Completed 229 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Timeline

Start
2022-11-18
Primary completion
2023-08-09
Completion
2023-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.025 % Other
Subject Ketotifen Small molecule 0.035 % Other

Indications